Dasatinib, a novel highly active oral Bcr-Abl/Src tyrosine kinase inhibitor, was used for the treatment of imatinib-resistant BCR-ABL-positive chronic myelogenous leukemia (CML) as a first line or for patients with resistance to imatinib [11]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.